Great Point Partners’s Humacyte HUMA Stock Holding History

Great Point Partners’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.93M	Hold	3,750,000	–	–	0.55%	38
2026 Q1	$2.28M	Buy	+3,750,000	New	+$3.9M	0.52%	37

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Great Point Partners's HUMA Position: Q2 2026 in Review

Great Point Partners held its Humacyte (HUMA) position steady in Q2 2026 at 3,750,000 shares worth $2.93M. The position accounts for 0.55% of the portfolio, ranked #38.

Great Point Partners first reported a position in HUMA in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Great Point Partners held 3,750,000 shares of Humacyte worth $2.93M as of Q2 2026.
Great Point Partners left its Humacyte share count unchanged in Q2 2026.
Humacyte made up 0.55% of Great Point Partners's portfolio in Q2 2026, its #38 holding.
Great Point Partners first reported a position in Humacyte in Q1 2026 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.